pharmaceuticals

pharmaceuticals Articles

A few biopharma companies have made massive runs on Tuesday morning.
Valeant Pharmaceuticals received a key FDA approval early on Thursday, but it seems to be a mixed blessing.
Merck saw its shares slip on Wednesday after the firm reported that it will be halting its mid-to-late-stage clinical trial for the treatment of Alzheimer’s disease.
Evoke Pharma saw its shares jump on Wednesday after the company issued an update that it received from the FDA.
Shares of Sage Therapeutics saw a handy gain on Monday after the company announced a successful mid-stage trial for the treatment of major depressive disorder.
Zosano Pharma saw its shares absolutely skyrocket on Monday after the firm gave an update on its late-stage trial for the treatment of migraines.
Teva beat estimates on earnings and revenues for both the quarter and the fiscal year and its outlook for 2017 is better than the consensus estimates.
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss.
Teva Pharmaceutical saw its shares tumble on Tuesday after the company announced a changing of the guard. This CEO departure may have been long overdue.
Neos Therapeutics saw its shares sink after the company announced that it had priced its secondary offering of common stock.
Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.
AMAG Pharmaceuticals shares took a sharp turn down after the company reported top-line results from its most recent pharmacokinetic study.
Merck reported disappointing fourth-quarter financial results before the markets opened on Thursday.
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) saw its shares make a huge gain on Tuesday after the firm reported a key legal decision in its favor. Essentially, the U.S. District Court for the...